Ifm_05-may 2022 Site

If you are looking for guidance based on this study's results:

The (often referred to simply as the IFM-05 study) focused on using lenalidomide as a maintenance treatment. IFM_05-May 2022

A significant number of patients (roughly 27%) had to stop the maintenance therapy early due to adverse side effects. If you are looking for guidance based on

Due to the risk of secondary cancers identified in the IFM-05 trial, long-term monitoring for new symptoms or blood changes is standard practice for those on this regimen. IFM_05-May 2022